Pasithea Therapeutics Announces Warrant Expiration and Nasdaq Delisting

What Happened Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced in an 8-K filed Sept. 16, 2026 that its publicly traded warrants (Nasdaq: KTTAW) will expire on September 17, 2026 per the Warrant Agency Agreement with VStock Transfer, LLC. Any warrants not exercised before that date will cease to be exercisable and will have no further value. The company will file a Form 25 to remove the warrants from listing and deregister them under Section 12(b) of the Exchange Act. Pasithea’s common stock (Nasdaq: KTTA) will continue trading on Nasdaq.

Key Details

• Warrant symbol: KTTAW; expiration date: September 17, 2026.
• Warrant agent: VStock Transfer, LLC; expiration is in accordance with the Warrant Agency Agreement.
• Warrants will stop trading on Nasdaq and a Form 25 (Notification of Removal from Listing and Registration) will be filed to delist/deregister them.
• Pasithea common stock (par value $0.0001) remains listed on Nasdaq under the ticker KTTA.

Why It Matters For investors holding KTTAW warrants, the key takeaway is that any warrants not exercised by September 17, 2026 will become worthless and will no longer trade on Nasdaq. Holders who wish to convert warrants into common shares must act before the expiration. For common-stock investors, this action only affects the warrants; Pasithea’s common stock will continue to trade under KTTA, so there is no change to the listing status of the company’s ordinary shares.